Market Research Logo

Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2016

Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2016 provides an overview of Small-Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Small-Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Small-Cell Lung Cancer Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Small-Cell Lung Cancer
Jun 06, 2016: Immunomedics Announces Sacituzumab Govitecan (IMMU-132) is Active in Patients With Previously-Treated Metastatic Small-Cell Lung Cancer
Jun 05, 2016: Results of Phase 1a/1b Study of AbbVies Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell Lung Cancer (SCLC)
Jun 05, 2016: OncoMed Presents Phase 1b Data on tarextumab at the 2016 ASCO Annual Meeting
Jun 02, 2016: Two-drug immunotherapy deemed safe for lung cancer patients, Moffitt study shows
May 19, 2016: Immunomedics to Report Updated Results for Sacituzumab Govitecan (IMMU-132) in Breast and Lung Cancers at Clinical Science Symposia of 2016 ASCO Annual Meeting
May 04, 2016: MOLOGEN to present next generation of TLR9 agonists at ASGCT 2016
Apr 29, 2016: Immunomedics Reports Responses With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Solid Cancers Who Failed Prior Checkpoint-Inhibitor Therapy
Apr 21, 2016: OncoMed Announces Updated Phase 1b Data for Tarextumab to be Presented at the 2016 ASCO Annual Meeting
Apr 18, 2016: AstraZeneca Presents Data on Next-generation Investigational Wee1 Inhibitor at the AACR 2016 Annual Meeting
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source
List of Tables
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2016*
Small-Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
Small-Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2016*
Small-Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
Small-Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Small-Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
List of Figures
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2016*
Small-Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
Small-Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2016*
Small-Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
Small-Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
Small-Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Small-Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
Small-Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
GlobalData Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report